 |
|
|
|
|
|
 Title: |
US6489298:
Contulakin-G, analogs thereof and uses thereof
[ Derwent Title ]
>> View Certificate of Correction for this publication
|
| Country: |
US United States of America
|
| |
| Inventor: |
Craig, A. Grey; Solana Beach, CA
Griffen, David; Greenville, NC
Olivera, Baldomero M.; Salt Lake City, UT
Watkins, Maren; Salt Lake City, UT
Hillyard, David R.; Salt Lake City, UT
Imperial, Julita; Salt Lake City, UT
Cruz, Lourdes J.; Manila, Philippines
Wagstaff, John D.; Salt Lake City, UT
Layer, Richard T.; Sandy, UT
Jones, Robert M.; Salt Lake City, UT
McCabe, R. Tyler; Salt Lake City, UT
|
| Assignee: |
Cognetix, Inc., Salt Lake City, UT
other patents from COGNETIX, INC. (810418) (approx. 4)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
2002-12-03
/ 2000-06-29
|
| Application Number: |
US2000000605991
|
| IPC Code: |
Advanced:
C07K 7/08;
C07K 9/00;
C07K 14/575;
C12N 15/12;
A61K 38/00;
Core:
C07K 7/00;
C07K 14/435;
more...
IPC-7:
A61K 38/00;
C07K 7/00;
C07K 7/08;
|
| ECLA Code: |
C07K7/08A; C07K9/00D; C07K14/575;
|
| U.S. Class: |
514/013;
514/002;
514/014;
530/324;
530/326;
530/325;
|
| Field of Search: |
514/002,13,14
530/324,326,325
|
| Government Interest: |
This invention was made with Government support under Grant No. GM-48677 awarded by the National Institutes of Health, Bethesda, Md. The United States Government has certain rights in the invention.
|
| Priority Number: |
| 2000-06-29 |
US2000000605991 |
| 1999-10-19 |
US1999000420797 |
| 1998-10-20 |
US1998000105015P |
| 1999-04-09 |
US1999000128561P |
| 1999-04-23 |
US1999000130661P |
|
| Abstract: |
The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr10-contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.
|
| Attorney, Agent or Firm: |
Rothwell, Figg, Ernst & Manbeck, P.C. ;
|
| Primary / Asst. Examiners: |
Romeo, David S.; Murphy, Joseph F.
|
| Maintenance Status: |
CC Certificate of Correction issued
View Certificate of Correction
|
| INPADOC Legal Status: |
Show legal status actions
Family Legal Status Report
|
|
|
|
|
|
|
| Parent Case: |
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a continuation of U.S. patent application Ser. No. 09/420,797 filed on Oct. 19, 1999. The present application is related to U.S. provisional patent application Serial No. 60/105,015, filed on Oct. 20, 1998, Serial No. 60/128,561, filed on April 9, 1999 and Serial No. 60/130,661, filed on Apr. 23, 1999, each incorporated herein by reference, and claims priority to each under 35 USC §119(e).
|
| Designated Country: |
AE AL AM AP AZ BA BB BG BR BY CA CN CR CU CZ DM EA EE GD GE GH GM HR HU ID IL AT BE CH CY DE DK ES FI FR GB GR IE
|
| Family: |
Show 21 known family members
|
First Claim:
Show all 11 claims |
What is claimed is:
1. A method for treating pain in an individual which comprises administering a therapeutically effective amount of an active agent to a individual in need of pain treatment, said active agent selected from the group consisting of:
- (a) contulakin-G comprising the amino acid sequence Xaa1 -Ser-Glu-Glu-Gly-Gly-Ser-Asn-Ala-Thr-Lys-Xaa2 -Tyr-Ile-Leu (SEQ ID NO:1), where Xaa1 is pyro-Glu, Xaa2 is proline or hydroxyproline and Thr10 is modified to contain O-glycan;
- b) a generic contulakin-G having the following general formula Xaa1 -Xaa2 -Xaa3 -Xaa3 -Gly-Gly-Xaa2 -Xaa4 -Xaa5 -Xaa6 -Xaa7 -Xaa8 -Xaa7 -Xaa9 -Xaa10 -lle-Leu (SEQ ID NO:2), where Xaa1 is pyro-Glu, Glu, Gln or γ-carboxy-Glu; Xaa2 is Ser, Thr or S-glycan modified Cys; Xaa3 is Glu or γ-carboxy-Glu; Xaa4 is Asn, N-glycan modified Asn or S-glycan modified Cys; Xaa5 is Ala or Gly; Xaa6 is Thr, Ser, S-glycan modified Cys, Tyr or any hydroxy containing unnatural amino acid; Xaa7 is Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, Arg, ornithine, homoarginine or any unnatural basic amino acid; Xaa8 is Ala, Gly, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, Arg, ornithine, homoarginine, any unnatural basic amino acid or X-Lys where X is (CH2)n, phenyl, --(CH2)m --(CH=CH)--(CH2)m H or --(CH2)m --(C.ident.C)--(CH2)m H in which n is 1-4 and m is 0-2; Xaa9 is Pro or hydroxy-Pro; and Xaa10 is Tyr, mono-iodo-Tyr, di-iodo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr, Trp, D-Trp, bromo-Trp, bromo-D-Trp, chloro-Trp, chloro-D-Trp, Phe, L-neo-Trp, or any unnatural aromatic amino acid, with the proviso that the generic contulakin-G is not desglycosylated contulakin-G;
- (c) a generic contulakin-G of (b) which is modified to contain an O-glycan, an S-glycan or an N-glycan;
- (d) a contulakin-G analog which comprises an N-terminal truncation of from 1 to 9 amino acids of the generic contulakin-G of (b);
- (e) a contulakin-G analog of (c), wherein an Ser-O-glycan, Thr-O-glycan or Cys-S-glycan is substituted for the amino acid residue at the truncated N-terminus;
- (f) a contulakin-G analog of (c), wherein an Ser-O-glycan, Thr-O-glycan or Cys-S-glycan is substituted for a residue at positions 2-9 of the generic contulakin-G; and
- (g) a contulakin-G analog which comprises an N-terminal truncation of 10 amino acids of the generic contulakin-G of (b) which is further modified to contain a Lys-N-glycan at residue 11 of the generic contulakin-G.
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
|
|
|
|
|
|
| Foreign References: |
None
|
| Other Abstract Info: |
DERABS C2000-364774
|
| Other References: |
Bannon et al. Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors. Science vol. 279 Jan. 2, 1998.*
Craig et al. Contulakin-G, an O-glycosylated Invertebrate Neurotensin. J. Biol. Chem. 274:20 pp. 13752-13759.*
Craig, A. G. et al. (1999). "Contulakin-G, an O-Glycosylated Invertabrate Neurotensin." J Biol Chem 274:13752-13759.
(8 pages)
Cited by 5 patents
[ISI abstract]
Vincent, J.P. et al. (1999). "Neurotensin and neurotensin receptors", Trends Pharmacol Sci. 20:302-309.
(10 pages)
Cited by 12 patents
[ISI abstract]
Shandra, O.A. et al. (1993). "[Effect of intracerebral injections of samatostatin and neurotensin on motor functions in seizure]." Fiziol Zh 39:76-82.
Clineschmidt, B.V. et al. (1979). "Neurotensin: antinocisponsive action in rodents." Eur J Pharmacol 54:129-139.
(11 pages)
Cited by 5 patents
Dubuc, I. et al. (1999). "The partial agonist properties of levocabastine in neurotensin-induced analgesia." Eur J Pharmacol 381:9-12.
(4 pages)
Cited by 5 patents
[ISI abstract]
Dubuc, I. et al. (1999). "Identification of the receptor subtype involved in the analgesic effect of neurotensin." J Neurosci 19:503-510.
(8 pages)
Cited by 6 patents
[ISI abstract]
Tyler, B.M. et al. (1998). "Evidence for additional neurotensin receptor subtypes: neurotensin analogs that distinguish between neurotensin-mediated hypthermia and antinociception." Brain Res 792:246-252.
(7 pages)
Cited by 8 patents
[ISI abstract]
Kinkead, B. et al. (1999). "Does neurotensin mediate the effects of antipsychotic drugs?"Biol Psychiatry 46:340-351.
(12 pages)
Cited by 6 patents
[ISI abstract]
Nemeroff, C.B. et al. (1992). "Neurotensin, antipsychotic drugs, and schizophrenia. Basic and clinical studies." Ann NY Acad Sci 668:146-156.
(11 pages)
Cited by 5 patents
[ISI abstract]
|
|
 Nominate this for the Gallery...
|
|
